Bod secures first prescription for MediCabilis cannabis oil and new research partner

Bod secures first prescription for MediCabilis cannabis oil and new research partner

It has been a long time coming for listed medicinal cannabis player Bod Australia (ASX: BDA), but they've finally secured their first prescription.

The company announced this morning that it has received its first prescription and required Special Access Scheme approvals for its MediCabilis cannabis oil product.

The approval should give Bod a boost in sales of cannabis oil in the near term.

Additionally, the company has announced its new research collaboration with Biologics Research Institute Australia (BRIA) the owners and operators of Cannabis Access Clinics.

Research will be conducted into the effects of the MediCabilis product on a broad range of patient outcomes.

The agreement is important for the company because once the research is completed MediCabilis will be made available to patients in Cannabis Access' network to prescribe when appropriate.

Cannabis Access Clinics have an extensive network of healthcare clinics assisting doctors and patients to navigate the (at times confusing) regulatory approvals for prescribing medicinal cannabis products in Australia and New Zealand.

The trial will provide feedback on MediCabilis' ability to treat a range of symptoms including anxiety, pain, post chemotherapy nausea & vomiting, and epilepsy.

Bod CEO Jo Patterson says today's news is important for the ongoing growth of the company and its ability to reach more patients in need of the product.

"This agreement is very beneficial for Bod, as it has not only resulted in the company receiving its first prescription for MediCabilis, but also provides us with a large pool of potential patients and prescribers from the Cannabis Access Clinics network that will provide ongoing feedback around our medicinal cannabis product offering," says Patterson.

Shares in Bod are down 1.74 per cent to $0.56 per share at 11.04am AEST.

READ MORE: The Cannabis Index: A complete guide to cannabis stocks on the ASX

Never miss a news update, subscribe here. Follow us on Facebook, LinkedIn, Instagram and Twitter.

Business News Australia

Enjoyed this article?

Don't miss out on the knowledge and insights to be gained from our daily news and features.

Subscribe today to unlock unlimited access to in-depth business coverage, expert analysis, and exclusive content across all devices.

Support independent journalism and stay informed with stories that matter to you.

Subscribe now and get 50% off your first year!

Four time-saving tips for automating your investment portfolio
Partner Content
In today's fast-paced investment landscape, time is a valuable commodity. Fortunately, w...
Etoro
Advertisement

Related Stories

Former AFL boss Gillon McLachlan to lead Tabcorp as new CEO

Former AFL boss Gillon McLachlan to lead Tabcorp as new CEO

After speculation was quashed that he would be joining Racing Victo...

Luxury fashion seller Azura hits profitability as AI plugs data gaps

Luxury fashion seller Azura hits profitability as AI plugs data gaps

An artificial intelligence (AI) overhaul has allowed Azura Fashion ...

“Not our desired outcome”: Telix withdraws from $300m Nasdaq IPO

“Not our desired outcome”: Telix withdraws from $300m Nasdaq IPO

Telix Pharmaceuticals (ASX: TLX), one of the nation’s largest...

CommBank joins new ‘intelligence loop’ to combat SMS phishing scams

CommBank joins new ‘intelligence loop’ to combat SMS phishing scams

In an effort to reduce the number of SMS phishing scam victims...